home / stock / invvy / invvy news


INVVY News and Press, Indivior PLC ADR From 07/28/22

Stock Information

Company Name: Indivior PLC ADR
Stock Symbol: INVVY
Market: OTC
Website: indivior.com

Menu

INVVY INVVY Quote INVVY Short INVVY News INVVY Articles INVVY Message Board
Get INVVY Alerts

News, Short Squeeze, Breakout and More Instantly...

INVVY - Indivior PLC ADR Non-GAAP EPS of $0.06, revenue of $221M

Indivior PLC ADR press release ( OTCPK:INVVY ): Q2 Non-GAAP EPS of $0.06. Revenue of $221M (+10.0% Y/Y). Outlook: Total FY 2022 expected NR range maintained at $840M to $900M (+10% vs. FY 2021 at the mid-point); Adjusted gross margin expected to be in the low- to mid-8...

INVVY - Indivior Announces H1 and Q2 2022 Financial Results

Indivior Announces H1 and Q2 2022 Financial Results PR Newswire SLOUGH, U.K. and RICHMOND, Va. , July 28 , 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced its financial results for the period ending June 30, 2022 . The earnings ...

INVVY - Indivior Names Nina DeLorenzo Chief Global Impact Officer

Indivior Names Nina DeLorenzo Chief Global Impact Officer PR Newswire RICHMOND, Va. , June 16, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) announces the appointment of Nina DeLorenzo as Chief Global Impact Officer. DeLorenzo will serve on the Execut...

INVVY - Indivior (INVVY) Presents At Jefferies Healthcare Conference - Slideshow

The following slide deck was published by Indivior PLC in conjunction with this event. For further details see: Indivior (INVVY) Presents At Jefferies Healthcare Conference - Slideshow

INVVY - Indivior Announces Seven Abstracts Accepted for Presentation at the 84th Annual Scientific Meeting of the College on Problems of Drug Dependence (CPDD)

Indivior Announces Seven Abstracts Accepted for Presentation at the 84th Annual Scientific Meeting of the College on Problems of Drug Dependence (CPDD) PR Newswire RICHMOND, Va. , June 9, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced ...

INVVY - Indivior Announces First Patient Included in Aelis Farma's Phase 2b Study Assessing the Efficacy, Safety and Tolerability of AEF0117 in Treatment-Seeking Subjects With Moderate to Severe Cannabis Use Disorder

Indivior Announces First Patient Included in Aelis Farma's Phase 2b Study Assessing the Efficacy, Safety and Tolerability of AEF0117 in Treatment-Seeking Subjects With Moderate to Severe Cannabis Use Disorder PR Newswire SLOUGH, England and RICHMOND, Va. , ...

INVVY - For Mental Health Awareness Month, Indivior Offers Hope for Opioid Use Disorder Recovery Through One Man's Inspiring Story

For Mental Health Awareness Month, Indivior Offers Hope for Opioid Use Disorder Recovery Through One Man's Inspiring Story PR Newswire RICHMOND, Va. , May 19, 2022 /PRNewswire/ -- May is Mental Health Awareness Month, a time to increase understanding of t...

INVVY - Indivior Lends Voice to Help Raise Awareness of Substance Use Disorder During Mental Health Awareness Month and National Fentanyl Awareness Day

Indivior Lends Voice to Help Raise Awareness of Substance Use Disorder During Mental Health Awareness Month and National Fentanyl Awareness Day PR Newswire RICHMOND, Va. , May 10, 2022 /PRNewswire/ -- May is Mental Health Awareness Month, a time to increa...

INVVY - Indivior PLC (INVVY) CEO Mark Crossley on Q1 2022 Results - Earnings Call Transcript

Indivior PLC (INVVY) Q1 2022 Results Earnings Conference Call April 28, 2022, 08:00 AM ET Company Participants Mark Crossley - Chief Executive Officer Ryan Preblick - Chief Financial Officer Christian Heidbreder - Chief Scientific Officer Conference Call Participants Paul Cuddon - Numis Secur...

INVVY - Indivior PLC 2022 Q1 - Results - Earnings Call Presentation

The following slide deck was published by Indivior PLC in conjunction with their 2022 Q1 earnings call. For further details see: Indivior PLC 2022 Q1 - Results - Earnings Call Presentation

Previous 10 Next 10